Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study.

By R. De Angelis, M. Sant, M. Coleman, S. Francisci, P. Baili, D. Pierannunzio, A. Trama, O. Visser, H. Brenner, E. Ardanaz and 6 more. The Lancet Oncology, 2014

1,840 citations recorded by the source corpus.

BACKGROUND Cancer survival is a key measure of the effectiveness of health-care systems. EUROCARE-the largest cooperative study of population-based cancer survival in Europe-has shown persistent differences between countries for cancer survival, although in general, cancer survival is improving. Major changes in cancer diagnosis, treatment, and rehabilitation occurred in the early 2000s. EUROCARE-5 assesses their effect on cancer survival in 29 European countries. METHODS In this retrospective observational study, we analysed data from 107 cancer registries for more than 10 million patients with cancer diagnosed up to 2007 and followed up to 2008. Uniform quality control procedures were applied to all datasets. For patients diagnosed 2000-07, we calculated 5-year relative survival for 46 cancers weighted by age and country. We also calculated country-specific and age-specific survival for ten common cancers, together with survival differences between time periods (for 1999-2001, 2002-04, and 2005-07). FINDINGS 5-year relative survival generally increased steadily over time for all European regions. The largest increases from 1999-2001 to 2005-07 were for prostate cancer (73.4% [95% CI 72.9-73.9] vs 81.7% [81.3-82.1]), non-Hodgkin lymphoma (53.8% [53.3-54.4] vs 60.4% [60.0-60.9]), and rectal cancer (52.1% [51.6-52.6] vs 57.6% [57.1-58.1]). Survival in eastern Europe was generally low and below the European mean, particularly for cancers with good or intermediate prognosis. Survival was highest for northern, central, and southern Europe. Survival in the UK and Ireland was intermediate for rectal cancer, breast cancer, prostate cancer, skin melanoma, and non-Hodgkin lymphoma, but low for kidney, stomach, ovarian, colon, and lung cancers. Survival for lung cancer in the UK and Ireland was much lower than for other regions for all periods, although results for lung cancer in some regions (central and eastern Europe) might be affected by overestimation. Survival usually decreased with age, although to different degrees depending on region and cancer type. INTERPRETATION The major advances in cancer management that occurred up to 2007 seem to have resulted in improved survival in Europe. Likely explanations of differences in survival between countries include: differences in stage at diagnosis and accessibility to good care, different diagnostic intensity and screening approaches, and differences in cancer biology. Variations in socioeconomic, lifestyle, and general health between populations might also have a role. Further studies are needed to fully interpret these findings and how to remedy disparities. FUNDING Italian Ministry of Health, European Commission, Compagnia di San Paolo Foundation, Cariplo Foundation.

Subfields: Economics and Econometrics, Epidemiology, Oncology

View Paper: https://www.semanticscholar.org/paper/5934dcd07bd82e49bb05fadc3efa55a31cec0913

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Economics and Econometrics

In Epidemiology

In Oncology

Citations in the corpus

Brentuximab Vedotin with Chemotherapy for CD30-Positive Peripheral T-cell Lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. (2018, background): “show that relative survival in the UK is intermediate-to-low for several common cancer types, compared with equivalent (Human Development Index) very high-income countries.(1) Cancers diagnosed at an advanced stage are invariably associated with poor prognosis; whereas finding cancer early offers pa”
Integrated genomic characterization of oesophageal carcinoma (2017, positive): “In our previous TCGA study27, we classified gastric tumours into four subtypes on the basis of having (1) Epstein-Barr virus (EBV) infection, (2) microsatellite instability (MSI), (3) chromosomal instability (CIN) and (4) genomic stability (GS), a group largely comprised of the diffuse histologic ty”
Global Cancer in Women: Burden and Trends (2017, background): “Because of early symptoms of uterine corpus cancer, early diagnosis and treatment is common in HICs, where 5-year survival is around 80% (82, 83).”
Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. (2014, background): “However, gastric cancer survival has remained unsatisfactorily low in most areas of the world [48].”
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, background): “This is especially true in Europe where the costs of care delivery [6] and cancer outcomes [7-9] vary substantially across Europe with the latter being influenced by the level”
International variations and trends in renal cell carcinoma incidence and mortality. (2015, background): “The survival advantage for the US population may reflect a high proportion of localised cancers (64%), but comparative information on stage distribution is not available from the EUROCARE-5 study [40,41].”
Epidemiology of Prostate Cancer (2019, background): “Moreover, survival has increased over time in all over Europe with the greatest improvement being observed in the Eastern European countries [31].”